Detail of "91421-42-0"

Reference

Determination of 9-nitrocamptothecin by precolumn derivatization and its metabolite 9-aminocamptothecin in a biological fluid using reversed-phase high-performance liquid chromatography with fluorescence detection

Determination of 9-nitrocamptothecin by precolumn derivatization and its metabolite 9-aminocamptothecin in a biological fluid using reversed-phase high-performance liquid chromatography with fluorescence detection. Zhang, Junhong; Burke, Thomas G.; Latus, Lori J. (Tigen Pharmaceutical, Inc., Lexington, KY 40508, USA). Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, 795(2), 309-318 (English) 2003 Elsevier B.V. CODEN: JCBAAI. ISSN: 1570-0232. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) A novel insol. topoisomerase I inhibitor, 9-nitrocamptothecin (9-NC), is in advanced stages of clin. development and has been used to treat a diverse array of tumor types, including breast, ovarian, pancreatic and hematol. malignancies. We have established a sensitive high-performance liq. chromatog. method using fluorescence detection for the quantitation of 9-NC. Non-fluorescent 9-NC is converted to fluorescent 9-aminocamptothecin (9-AC) via a one-step pre-column deriv. reaction. The quant. limit of 9-NC was 1 ng/mL and the method was reproducible with the resp. intra- and inter-day variability falling below 5.0 and 9.0%. The detn. of both 9-NC and its metabolite 9-AC in dog plasma was also achieved using the same chromatog. and detection conditions. In dog plasma, the quant. 91421-43-1 and 91421-42-0 which are cas registry numbers of substances are two of reagents here. limits of 9-AC and 9-NC were 0.25 and 1 ng/mL, resp. The presence of 9-AC in the samples yielded no interference with the detn. of 9-NC. However, individual matrixes can affect the conversion efficiency of 9-NC, thus indicating that std. samples should be run for each matrix. .

Induction of apoptosis in malignant and camptothecin-resistant human cells

Induction of apoptosis in malignant and camptothecin-resistant human cells. Chatterjee, Devasis; Wyche, James H.; Pantazis, Panayotis ( Department of Molecular Biology, Cell Biology, Brown University, Providence, RI, USA). Annals of the New York Academy of Sciences, 803(Camptothecins), 143-156 (English) 1996 New York Academy of Sciences. CODEN: ANYAA9. ISSN: 0077-8923. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Flow cytometry studies demonstrate that androgen-independent human prostate carcinoma DU-145 cells are arrested at the G1-phase of the cell cycle in the presence of suramin, but they die by apoptosis in the presence of 9-nitrocamptothecin. Addn. of cytostatic concns. of suramin increases the apoptotic action of 9-nitrocamptothecin on DU-145 cells, and induces apoptosis in 9-nitrocamptothecin-resistant DU-145/RC cells that were derived from the parental DU-145 cells by continuous exposure to progressively increased concns. of 9-nitrocamptothecin. In addn. 145-63-1 and 91421-42-0 are also in the experiment., the topoisomerase II-directed drug etoposide exerts more extensive apoptotic action on DU-145/RC than DU-145 cells. Increased resistance of DU-145 cells to 9-nitrocamptothecin and collaterally increased sensitivity to etoposide and suramin appear to correlate with alterations in the structure rather than synthesis of topoisomerases and possibly with sp. cellular proteins that regulate apoptosis. The results suggest that etoposide and suramin may be successful alternative treatments for 9-nitrocamptothecin-resistant androgen-independent prostate cancer. .